학술논문
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Document Type
Article
Author
Source
In: Journal of the European Academy of Dermatology and Venereology . (Journal of the European Academy of Dermatology and Venereology, 2024)
Subject
Language
English
ISSN
14683083
09269959
09269959